Clozapine-induced myocarditis: is mandatory monitoring warranted for its early recognition?
- PMID: 24587933
- PMCID: PMC3920926
- DOI: 10.1155/2014/513108
Clozapine-induced myocarditis: is mandatory monitoring warranted for its early recognition?
Abstract
Clozapine is an atypical antipsychotic used for treatment resistant schizophrenia. Its potential to induce agranulocytosis is well known but it can also cause myocarditis. Clozapine is the only antipsychotic known to induce this side effect, typically early in the treatment, and literature is scarce on this condition. We are presenting a case report of a 21-year-old schizophrenic male who developed myocarditis within 3 weeks of starting on clozapine for his treatment resistant psychosis. We then aim to review some of the available literature and raise awareness among physicians as this condition can potentially be fatal if not detected early.
References
-
- Hägg S, Spigset O, Bahons AB, Söderström TG. Myocarditis related to clozapine treatment. Journal of Clinical Psychopharmacology. 2001;21(4):382–388. - PubMed
-
- Magnani JW, Dec GW. Myocarditis: current trends in diagnosis and treatment. Circulation. 2006;113(6):876–890. - PubMed
-
- Kilian JG, Kerr K, Lawrence C, Celermajer DS. Myocarditis and cardiomyopathy associated with clozapine. The Lancet. 1999;354(9193):1841–1845. - PubMed
-
- Haas SJ, Hill R, Krum H, et al. Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003. Drug Safety. 2007;30(1):47–57. - PubMed
-
- Merrill DB, Dec GW, Goff DC. Adverse cardiac effects associated with clozapine. Journal of Clinical Psychopharmacology. 2005;25(1):32–41. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
